AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31327563
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of supervised primaquine (1·0 mg/kg per day)
Trial: 31327563
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of supervised primaquine (0·5 mg/kg per day)
Trial: 22924607
Drug: High-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cholecalciferol (4000-100,000 IU per week)
Trial: 16042223
Drug: IFNβ‐1a‐Avonex 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNβ‐1a‐Avonex 30 μg intramuscularly once weekly for six years
Trial: 9112170
Drug: Trephination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trephination with scleral auto-implant plug soaked with Mitomycin-C (0.2 mg/ml for 5 minutes)
Trial: 28838290
Drug: Modified Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Behavioral Activation Treatment (MBAT) for 8 weeks
Trial: 26383577
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (Control)
Trial: 26711160
Drug: Dronabinol 20
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol 20 mg three times a day and lofexidine 0.6 mg three times a day
Trial: 24853059
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural treatment protocol (CBSPp) with treatment as usual (TAU), 24 sessions
Trial: 24853059
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural treatment protocol (CBSPp)
Trial: 20931422
Drug: Probiotic-containing yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic-containing yogurt (Bifidobacterium DN-173 010-1010 cfu/g) 125 ml before breakfast for 14 days
Trial: 20931422
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (pantoprazole 40 mg b.i.d., amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d. for 14 days)
Trial: 12352805
Drug: Protease inhibitors
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitors (indinavir, saquinavir, ritonavir, nelfinavir)
Trial: 9935109
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg of IM progesterone given 12 hours before oocyte retrieval
Trial: 9935109
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of IM progesterone given on the day of oocyte retrieval
Trial: 6160639
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg per day for one week
Trial: 30567527
Drug: FOLFOX-4 chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-4 chemotherapy (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, 5-fluorouracil bolus 400 mg/m2 + infusion 600 mg/m2 for 2 days every 3 weeks)
Trial: 30567527
Drug: Topotecan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.5 mg/m2 every three weeks)
Trial: 18619971
Drug: Vaccine consisting
RxNorm normalized name: IMMUNOTHERAPEUTIC VACCINE CONSISTING OF (PAM)2-LYS-SER-SER-GLN-TYR-ILE-LYS-ALA-ASN-SER-LYS-PHE-ILE-GLY-ILE-THR-GLU-ALA-ALA-ALA-PHE-LEU-PRO-SER-ASP-PHE-PHE-PRO-SER-VAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine consisting of recombinant VacA, CagA, and NAP with aluminium hydroxide as an adjuvant
Trial: 18619971
Drug: Vaccine consisting
RxNorm normalized name: IMMUNOTHERAPEUTIC VACCINE CONSISTING OF (PAM)2-LYS-SER-SER-GLN-TYR-ILE-LYS-ALA-ASN-SER-LYS-PHE-ILE-GLY-ILE-THR-GLU-ALA-ALA-ALA-PHE-LEU-PRO-SER-ASP-PHE-PHE-PRO-SER-VAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine consisting of recombinant VacA, CagA, and NAP
Trial: 14671161
Drug: rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH treatment (6 microg/kg.d)
Trial: 8997054
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural administration of fentanyl 33 micrograms/ml with 0.17% bupivacaine
Trial: 8997054
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural administration of morphine 0.21 mg/ml with 0.17% bupivacaine
Trial: 8997054
Drug: Bolus epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus epidural administration of fentanyl 100 micrograms
Trial: 8997054
Drug: Bolus epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus epidural administration of morphine 3 mg
Trial: 2581855
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (cyclophosphamide, vincristine and prednisone)
Trial: 30476976
Drug: Dapsone therapy
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone therapy for CSU
Trial: 25147733
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - ten weekly intervention sessions
Trial: 7782724
Drug: Fasting blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting blood glucose (FBG) cut-off value of 6.7 mmol L-1
Trial: 7782724
Drug: Fasting blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting blood glucose (FBG) cut-off value of 6.0 mmol L-1
Trial: 7782724
Drug: Fasting blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting blood glucose (FBG) cut-off value of 4.8 mmol L-1
Trial: 7782724
Drug: Fasting blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting blood glucose (FBG) optimal cut-off value of 5.3 mmol L-1
Trial: 7782724
Drug: 2-h oral
RxNorm normalized name: dextroamphetamine 2 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-h oral glucose tolerance test (OGTT)
Trial: 2371368
Drug: Haloperidol plasma
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol plasma level 2‐13 ng/ml
Trial: 2371368
Drug: Haloperidol plasma
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol plasma level 13.1‐24 ng/ml
Trial: 2371368
Drug: Haloperidol plasma
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol plasma level 24.1‐35 ng/ml
Trial: 1744385
Drug: 0.1 N
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 N HCl infusion
Trial: 27415
Drug: Various test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various test solutions (distilled water, 0.9% NaCl, 1.8% NaCl, 3.6% NaCl, 0.1 N HCl, 0.2 N HCl)
Trial: 27415
Drug: 0.1 N
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 N HCl infusion with increased rate
Trial: 27415
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of intraluminal fluid
Trial: 27415
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of bolus injection
Trial: 30498908
Drug: Growth factor-based
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth factor-based therapies
Trial: 30498908
Drug: Small molecule-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule-based therapies
Trial: 27548030
Drug: Community-implemented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-implemented treatment (CIT)
Trial: 15349137
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (66 mg elemental iron)
Trial: 17435611
Drug: Iron polymaltose
RxNorm normalized name: iron polymaltose
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron polymaltose complex (IPC) (100 mg elemental iron)
Trial: 15349137
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug treatment (baseline)
Trial: 11332584
Drug: 50microg/day of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50microg/day of transdermal 17beta‐estradiol
Trial: 9434661
Drug: Zinc (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (25 mg as zinc sulfate)
Trial: 9434661
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A and Zinc (800 micrograms retinol palmitate and 25 mg as zinc sulfate)
Trial: 7859694
Drug: Sorbitol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (2 x 15 g)
Trial: 7859694
Drug: Maltitol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltitol (2 x 15 g)
Trial: 7859694
Drug: Isomalt (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomalt (2 x 15 g)
Trial: 7859694
Drug: Sorbitol (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (5, 10, or 20 g)
Trial: 7859694
Drug: Isomalt (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomalt (5, 10, or 20 g)
Trial: 7859694
Drug: Polyols (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyols (2 x 15 g intake)
Trial: 2913680
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 vaginal tablets (0.5 mg) intravaginally every 6 hours
Trial: 19295201
Drug: Urokinase (UK)
DrugBank: Urokinase (DB00013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urokinase (UK) administered intraventricularly every 12 hours until clinical response permitted EVD removal
Trial: 19295201
Drug: Placebo (Pcb)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Pcb) administered intraventricularly every 12 hours until clinical response permitted EVD removal
Trial: 15087045
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg cabergoline
Trial: 15087045
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg cabergoline
Trial: 3758244
Drug: Dextromethorphan-salbutamol combination
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan-salbutamol combination
Trial: 12575602
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (megestrol acetate and Chinese medicine)
Trial: 31405927
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of the D2 antagonist haloperidol
Trial: 28927869
Drug: initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: initial combination therapy including prednisone
Trial: 28927869
Drug: sequential DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential DMARD monotherapy
Trial: 21415052
Drug: step-up combination
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: step-up combination therapy
Trial: 25283471
Drug: Oral lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral lenalidomide 10 mg once daily
Trial: 15659723
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus esomeprazole (80 mg aspirin daily + 20 mg esomeprazole twice daily)
Trial: 7485927
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 3 g/day for 5 days
Trial: 31103018
Drug: Oxytocin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (40 IU via nasal spray)
Trial: 23937007
Drug: Hearing aids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hearing aids combined with psychological counseling therapy
Trial: 23937007
Drug: Counseling therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling therapy only
Trial: 15167120
Drug: 131I thyroid
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 131I thyroid doses
Trial: 11848001
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate orally the evening before, clear liquid the day of the exam, and two Dulcolax suppositories the day of the exam
Trial: 9204088
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel + Benzoyl peroxide
Trial: 9204088
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel + Clindamycin phosphate
Trial: 9204088
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel + Erythromycin
Trial: 8894261
Drug: Atenolol (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50-100 mg/day)
Trial: 28734853
Drug: D25 (dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D25 (dexmedetomidine 25 μg kg−1)
Trial: 28734853
Drug: D25M300 (dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D25M300 (dexmedetomidine 25 μg kg−1 + MK-467 300 μg kg−1)
Trial: 28734853
Drug: D25M600 (dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D25M600 (dexmedetomidine 25 μg kg−1 + MK-467 600 μg kg−1)
Trial: 28734853
Drug: D25M1200 (dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D25M1200 (dexmedetomidine 25 μg kg−1 + MK-467 1200 μg kg−1)
Trial: 28734853
Drug: M600 (MK-467
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M600 (MK-467 600 μg kg−1)
Trial: 28734853
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments with dexmedetomidine
Trial: 19506498
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (2 microg/kg)
Trial: 16484572
Drug: Aged garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged garlic extract (AGE) administered for 6 months
Trial: 16484572
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 6 months
Trial: 10386195
Drug: Ketoconazole (400‐800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400‐800 mg/d p.o.)
Trial: 1520082
Drug: Threonine at
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Threonine at a total daily dose of 7.5 g
Trial: 6873148
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg at 20 h
Trial: 6873148
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg at 8 h
Trial: 6873148
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg at 12 h
Trial: 17151158
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Trial: 26075840
Drug: Perphenazine (first-generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (first-generation antipsychotic)
Trial: 10543928
Drug: ramipril 1.25
RxNorm normalized name: ramipril 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril 1.25 mg/day
Trial: 6392223
Drug: AT1727 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AT1727 treatment side effects
Trial: 11898235
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise during chemotherapy
Trial: 23113947
Drug: Pyronaridine-artesunate granules
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pyronaridine-artesunate granules (60/20 mg) once daily for three days
Trial: 23113947
Drug: Artemether-lumefantrine crushed
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine crushed tablets (20/120 mg) twice daily for three days
Trial: 19648772
Drug: Domperidone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (0.3 mg/kg/8 h p.o. for at least 2 days)
Trial: 18348296
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy after primary surgery
Trial: 12509376
Drug: Pharmacists consulting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists consulting to family physicians for medication optimization
Trial: 12509376
Drug: Medication use,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication use, health care utilization, and general health
Trial: 7532157
Drug: Intra-arterial hepatic
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial hepatic route (i.a.h.) administration of Cisplatin (CDDP)
Trial: 7532157
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) administration of Cisplatin (CDDP)
Trial: 1821700
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of milnacipran (300 mg daily for 2 weeks, then 150 mg daily for 2 weeks)
Trial: 1821700
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of milnacipran (200 mg daily for 4 weeks)
Trial: 1821700
Drug: Fluvoxamine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (200 mg daily for 4 weeks)
Trial: 27140216
Drug: Midazolam sequential
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam sequential with dexmedetomidine (loading dose of midazolam at 0.3-3 mg/kg·h for 24 h before extubation, followed by dexmedetomidine infusion at 0.2-1 μg/kg·h until extubation)
Trial: 27140216
Drug: Midazolam (0.3-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.3-3 mg/kg·h until extubation)
Trial: 27140216
Drug: Midazolam sequential
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam sequential with dexmedetomidine
Trial: 24815795
Drug: Sildenafil (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (titrated to 80 mg, three times daily, as tolerated)
Trial: 22348451
Drug: Low-dose melatonin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose melatonin (0.4mg)
Trial: 22348451
Drug: High-dose melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melatonin (4.0mg)
Trial: 18822087
Drug: Apomorphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine infusion
Trial: 11357167
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist (IL-1ra) 150 mg/d
Trial: 11357167
Drug: IL-1ra 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-1ra 1.0 mg/kg/d
Trial: 11357167
Drug: IL-1ra 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-1ra 2.0 mg/kg/d
Trial: 9580575
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg LAAM
Trial: 9580575
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg LAAM
Trial: 8111576
Drug: HCl infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCl infusion (patients)
Trial: 23686001
Drug: Panretinal photocoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panretinal photocoagulation (PRP) associated with intravitreal bevacizumab (IVB) injections
Trial: 20946162
Drug: Early rehabilitation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rehabilitation (sildenafil citrate twice weekly starting at 2 months postoperatively)